收费全文 | 2535098篇 |
免费 | 204368篇 |
国内免费 | 4464篇 |
医药卫生 | 2743930篇 |
2019年 | 20515篇 |
2018年 | 30079篇 |
2017年 | 22658篇 |
2016年 | 24394篇 |
2015年 | 27613篇 |
2014年 | 38422篇 |
2013年 | 58487篇 |
2012年 | 82317篇 |
2011年 | 86019篇 |
2010年 | 49168篇 |
2009年 | 45983篇 |
2008年 | 80375篇 |
2007年 | 85485篇 |
2006年 | 85390篇 |
2005年 | 83140篇 |
2004年 | 79670篇 |
2003年 | 76497篇 |
2002年 | 74988篇 |
2001年 | 115144篇 |
2000年 | 119126篇 |
1999年 | 100267篇 |
1998年 | 26783篇 |
1997年 | 24285篇 |
1996年 | 24182篇 |
1995年 | 24891篇 |
1994年 | 23422篇 |
1993年 | 21774篇 |
1992年 | 80800篇 |
1991年 | 77757篇 |
1990年 | 74862篇 |
1989年 | 72027篇 |
1988年 | 66985篇 |
1987年 | 65896篇 |
1986年 | 62358篇 |
1985年 | 59340篇 |
1984年 | 44934篇 |
1983年 | 38217篇 |
1982年 | 23231篇 |
1981年 | 20578篇 |
1979年 | 41920篇 |
1978年 | 29387篇 |
1977年 | 24698篇 |
1976年 | 23062篇 |
1975年 | 24315篇 |
1974年 | 30084篇 |
1973年 | 28538篇 |
1972年 | 26725篇 |
1971年 | 24606篇 |
1970年 | 23197篇 |
1969年 | 21541篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献